

Dr Lal PathLabs Limited records revenue of Rs 703 Cr with a growth of 16.6% in Q4 FY26

New Delhi, India, April 30, 2026 – Dr Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended March 31, 2026.

Consolidated Performance Highlights: Q4 FY26

- Revenue increased by 16.6% in Q4 FY26
- EBITDA for Q4 FY26 increased by 10.5% with a margin of 26.6%
- PAT for Q4 FY26 is Rs 132 Cr. with a margin for of 18.8%
- Final Dividend of 40% i.e. Rs. 4 per share.
- Cash and Cash equivalents as on 31st March, 2026 is Rs. 1,526 Cr.

Financial Overview (Consolidated) in Rs Cr

Particulars	Q4			Full Year		
	FY26	FY25	Gr %	FY26	FY25	Gr %
Revenue	703	603	16.6%	2763	2461	12.2%
Material consumed	135	118		535	481	
Employee benefit Expenses	129	109		533#	456	
Fees to collection centres	101	78		402	342	
Other Expenses	151	129		540	487	
EBITDA	187	169	10.5%	752	696	8.2%
<i>Margins</i>	<i>26.6%</i>	<i>28.1%</i>		<i>27.2%</i>	<i>28.3%</i>	
Other Income	24	26		101	93	
Depreciation Cost	45	36		162	142	
Finance Cost	6	5		23	22	
PBT	160	154	4.2%	669	625	7.1%
<i>Margins</i>	<i>22.8%</i>	<i>25.5%</i>		<i>24.2%</i>	<i>25.4%</i>	
Income Tax	28	(2)		159	133	
PAT	132	156	-15.1%	510	492	3.6%
<i>Margins</i>	<i>18.8%</i>	<i>25.8%</i>		<i>18.4%</i>	<i>20.0%</i>	
EPS	7.9	9.3	-15.4%	30.2	29.2	3.4%
Impact of new Labour Codes	-	-		30	-	
One Time Tax Benefit SDPL Liquidation	-	(41)		-	(41)	
Normalized EBITDA*	187	169	10.5%	783	696	12.5%
<i>Margins</i>	<i>26.6%</i>	<i>28.1%</i>		<i>28.3%</i>	<i>28.3%</i>	
Normalized PAT*	132	115	15.1%	532	451	17.9%
<i>Margins</i>	<i>18.8%</i>	<i>19.1%</i>		<i>19.3%</i>	<i>18.3%</i>	

*Excluding one-time exceptional items

#Including one-time impact of Labour Code



About Dr Lal PathLabs Limited

Dr Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its' integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2026 the company has 312 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore & Mumbai), 7,727 Patient Service Centers (PSCs) and 13,935 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Ved Goel
Group Chief Financial Officer &
CEO- International Business
Dr Lal PathLabs Limited

+91 124 3016500
cfo@lalpathlabs.com

Kritika Khatwani
Adfactors PR

+91 8604801332
kritika.khatwani@adfactorspr.com

For further information on Dr Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.